Investigating how transposable elements affect immune aging in sepsis patients
Role of Transposable Elements in Septic Immune Aging
This study looks at how certain genetic elements might affect the immune system and health outcomes in people with sepsis in the ICU.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 116 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Drugs / interventions | CAR-T |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT06809868 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between transposable elements and patient outcomes in individuals suffering from sepsis. It seeks to determine whether these elements contribute to premature immune aging, correlate with increased mortality, and are linked to a higher incidence of secondary infections in ICU patients. Participants will have blood samples collected for RNA and DNA sequencing without any additional interventions. The study focuses on patients admitted to the ICU with sepsis, utilizing established criteria for inclusion.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 or older who are admitted to the ICU with sepsis and have a SOFA score of at least 2.
Not a fit: Patients on organ transplantation immunosuppression, those with preexisting leukopenia, or cancer patients receiving CAR-T therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of sepsis, potentially enhancing patient outcomes.
How similar studies have performed: While the specific approach of examining transposable elements in sepsis is novel, related studies have shown the importance of immune aging in critical conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older * Admitted to ICU with sepsis (Sepsis 3 Criteria) * SOFA score of at least 2 at time of enrollment Exclusion Criteria: * Patients on organ transplantation immunosuppression * Patients with preexisting leukopenia * Cancer patients receiving CAR-T therapy * Patients who are under 18 years of age or otherwise deemed pediatric * Patients with an ongoing bleeding diathesis (ie: DIC, hemorrhagic shock) * Patients with a chronic hemoglobin below 7.0 * Patients who, prior to their ICU admission, are blood transfusion dependent
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Alexendar R Perez, M.D., Ph.D — University of California, San Francisco
- Study coordinator: Alexendar R Perez, M.D., Ph.D
- Email: Alexendar.Perez@ucsf.edu
- Phone: 415-476-1000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.